DaVita Inc. (NYSE:DVA) Shares Purchased by KBC Group NV

KBC Group NV raised its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 27.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 313,519 shares of the company's stock after purchasing an additional 67,250 shares during the quarter. KBC Group NV owned 0.38% of DaVita worth $51,395,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its holdings in DaVita by 2,335.6% in the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company's stock valued at $1,483,000 after buying an additional 10,300 shares during the period. Sei Investments Co. increased its holdings in DaVita by 21.3% in the 1st quarter. Sei Investments Co. now owns 41,952 shares of the company's stock valued at $5,790,000 after purchasing an additional 7,371 shares during the last quarter. BOKF NA lifted its stake in DaVita by 286,550.0% during the first quarter. BOKF NA now owns 5,733 shares of the company's stock worth $790,000 after purchasing an additional 5,731 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after buying an additional 11,454 shares during the period. Finally, Comerica Bank grew its stake in shares of DaVita by 41.4% in the first quarter. Comerica Bank now owns 34,431 shares of the company's stock valued at $4,753,000 after buying an additional 10,074 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Stock Up 3.8 %

NYSE DVA traded up $5.92 on Friday, hitting $160.28. 1,162,963 shares of the stock were exchanged, compared to its average volume of 821,323. DaVita Inc. has a fifty-two week low of $92.68 and a fifty-two week high of $168.50. The company has a 50-day moving average price of $157.57 and a 200-day moving average price of $147.35. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The company has a market cap of $13.14 billion, a PE ratio of 16.65, a PEG ratio of 0.89 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company earned $2.85 EPS. Sell-side analysts anticipate that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the company's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares of the company's stock, valued at $17,286,243.86. This represents a 36.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 156,086 shares of company stock worth $24,807,161 over the last 90 days. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on DVA. TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a report on Wednesday, July 24th. Bank of America raised their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research note on Wednesday, August 7th. UBS Group upped their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Finally, Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, DaVita currently has an average rating of "Hold" and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.